

05<sup>th</sup> August 2019

The Manager-Listing BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 The Manager- Listing National Stock Exchange of India Ltd., Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub - Outcome of Board Meeting.

Ref – Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements).

We inform you that the Board of Directors of the Company, at its Meeting held today i.e. on 05<sup>th</sup> August 2019, has approved the standalone unaudited financial results, for the quarter ended 30<sup>th</sup> June, 2019.

Pursuant to above-referred regulations, we enclose the following documents.

1. Statement of Financial Results for the quarter ended 30th June 2019.

2. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results,

The Meeting Commenced on 02:00 p.m. and Concluded on 04:15 p.m.

The above information will be made available on the Company's website <u>www.nathbiogenes.com</u>.

You are requested to take the above information on record.

Thanking You

For Nath Bio-Genes (India) Limited

MILE

Devinder Khurana Chief Financial Officer



Nath House, Nath Road, Aurangabad - 431005 (MS) Tel : 0240-2376314/5/6/7
Email : info@nathseeds.com www.nathbiogenes.com

1, Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel : 022-22871001, 22875653/4/5

NATH SECTS Nath Bio-Genes (1) Ltd. (CH LOTINGARTORER, CO72842) STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND 3 MONTHS ENDED 30/06/2019							
		Quarter Ended			Three Months Ended		Year Ended
Na	Particulars	30/06/2019 Unaudited	31/03/2019 Audited	30/06/2018 Unaudited	30/06/2019 Unaudited	30/06/2018 Unaudited	31/03/2019 Audited
1	Income						and the second s
	(a) Revenue from operations	16531.94	5230.91	12696.22	16531.94	12696.22	23092.8
	(b) Other Operating Income	62.88	42.23	64.67	62.88	64.67	227.3
н	Total Income Expenses	16594.82	5273.14	12760.89	16594.82	12760.89	23320.2
	a) Cost of Material Consumed	4605.58	4715.11	2252.71	4605.58	2252.71	13061.8
an-	b) Purchase of Stock-in-Trade	133.04	283.06	22.86	133.04	22.86	549.1
	c) Changes in Inventory of Finished Goods						- 1011
	& Work in Progress	3638.15	(2158.31)	4322.63	3638.15	4322.63	(3046.0
	d) Employee Benefit Expense	397.36	441.01	487.89	397.36	487.89	1642.8
	e) Finance Costs	173.06	134.76	111.50	173.06	111.50	520.4
	f) Depreciation & Amortisation Expenses	35.00	39.66	35.00	35.00	35.00	144,6
	g) Selling & Distribution Expenses	3584.80	775.59	2339.12	3584.80	2339.12	4418.4
	h) Admin & R&D Expenditure	481.33	594.65	537.68	481.33	537 68	2142.1
	Total Expenses	13048.32	4825.53	10109.39	13048.32	10109.39	19433.4
	Profit before Exceptional Items & Tax (I - II)	3546.50	447.61	2651.49	3546.50	2651.49	3886.8
IV	Exceptional items Income/(Expenses)	0.00	0.00	0.00	0.00	0.00	0.0
٧	Profit Before Tax (III+IV)	3546.50	447.61	2651.49	3546.50	2651.49	3886.8
VI	Tax Expense						
	(a) Current Tax	20.75	(116.42)	50.00	20.75	50.00	10.9
	(b) Earlier Year Tax	0.00	0.00	0.00	0.00	0.00	18.7
	(c) Deferred Tax	0.00	13.79	0.00	0.00	0.00	13.7
	Net Profit for the period (V-VI)	3525.75	550.24	2601.49	3525.75	2601.49	3843.3
VIII	Other Comprehensive Income						
	1. (a) Items that will not be reclassified to			J			
	Profit or Loss	0.00	8.39	0.00	0.00	0.00	8.3
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.0
		0.00	0.00	0.00	0.00	0.00	0.0
	2. (a) Items that will be reclassified to Profit or Loss	. 0.00	0.00	0.00	0.00	0.00	0.0
	(b) Income tax relating to items that will be	ę 0.00	0.00	0.00	0.00	0.00	0.0
	reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.0
	Total other Comprehensive Income	0.00	8.39	00.0	0.00	0.00	8.3
IX	Total Comprehensive Income for the period (VII +						
-	VIII)	3525.75	541.85	2601.49	3525.75	2601.49	3834.9
	Paid Up Equity Share Capital						
X	(Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900.40	1900.40	1900.4
	Reserves (excluding Revaluation • ;						
	Reserves) as per balance sheet of previous	52383.41	48857.67	47624.21	52383.41	47624.21	48857.6
XII	Earning per share (of Rs 10/- each) (not annualised)	02000.91					
	Basic & Diluted	18.55	2.90	13.69	18.55	13.69	20.2

## NOTES:

(1) The financial results were reviewed by the Audit Committee in meeting held on 03 August 2019 and were thereafter approved by the Board of Directors at its meeting held on 05 August 2019.

(2) The company is dealing in one major product segment, i.e. Seed Cultivation.

(3) The figures have been regrouped/rearranged where ever necessary.

Place : Aurangabad

Date : 05 Aug 2019

FOR NATH BIO-GENES (INDIA) LTD

Im Satish Kagliwal MANAGING DIRECTOR DIN 00119601

8 THIA

CHARTED BY ACCO.

CHARTERED ACCOUNTANT M.NO.: 124781 FRN NO.:127769W

KHOPOL

ASHOK R. MAJETHIA & CO. Chartered Accountants FRN No.: 127769W Shunte ASHOK R. MAJETHIA

MEMBERSHIP NO. : 124781

Regd. Office : Nath Hou

## ASHOK R. MAJETHIA

BCom. F.C.A CHARTERED ACCOUNTANT Ashok R. Majethia & Co. Chartered Accountants Utsav Complex, Office No. 7, Bazar Peth, Dist. Raigad, Khopoli – 410 203 Tel :- (02192) 269908 Mobile :- 9404711539 / 9372169952 Email :- ashokmajethia@redifmail.com

## LIMITED REVIEW REPORT

To The Board of Directors of Nath Bio-Genes (India) Limited

- 1. We have reviewed the accompanying statement of unaudited financial results for the quarter ended 30<sup>th</sup> June 2019 (the Statement) of NATH BIO-GENES (INDIA) LIMITED (the Company). This statement has been prepared by the Company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 (the "Listing Regulation, 2015" read with SEBI circular dated July 05, 2016 which has been initialed by us for identification purposes.
- 2. The preparation of the statement in accordance with the the recognition and measurement principle laid down in the Indian Acconting Standard 34 –"Interim Financial Reporting" as prescribed under section 133 of the Companies Act, 2013 read with the rule no 3 of the Companies (Acconting Standard Rule) 2015, as amended read with the circular, is the responsibility of the Company's management and has been approved by the Baord of Directors of the Company in the meeting held on 05<sup>th</sup> August 2019. Our responsibility is to express a conclusion on statements based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement.



- 4. A review is limited primarily to enquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement has not been prepared in all material respect in accordance with Ind-AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of regulation 33 of the Listing Regulations, 2015 read with SEBI Circular dated 5<sup>th</sup> July 2015 including the manner in which it is to be disclosed, or that it contains any material mis-statement.

For Ashok R Majethia Chartered Accountants FRN: 127769W

Ashok Majethia Proprietor M No: 124781

Place: Aurangabad Date: 05<sup>th</sup> August 2019

1 1

